- Thin, offensive smelling vaginal discharge
- Vaginal odour
Frequently recurs
NB: Not typically associated with itch, soreness or irritation
Welcome to the Right Decision Service (RDS) newsletter for October 2024.
Development of the contingency solutions to maximise RDS resilience and minimise risk of future outages is in progress, aiming for completion by Christmas. As a reminder, these contingency arrangements are:
In the meantime, a gentle reminder to encourage users to download essential clinical toolkits to their mobile devices so that there is an offline version always available.
A new scheduled deployment with minor improvements drawn from support tickets, externally funded projects, information related to outages, and feature requests will take place in early December. Key improvements planned are:
We are also seeking approval to use the NHS Scotland logo and title for the RDS app on the app stores to help with audience engagement and clarity around the provenance of RDS.
We are still hopeful that user acceptance testing for at least the Search and browse enhancements can take place before Christmas. Thank you for your patience and understanding in waiting for these improvements. Timescales have been pushed back by old app migration challenges, work to address outages, and most recently implementing the contingency arrangements.
We are aware that there continue to be some issues around a number of RDS support tickets, in part due to constraints around visibility for the RDS team of the tickets in the existing support portal. We are investigating the potential to move to a new support ticket requesting system from early in the new year. We will organise the proposed webinar around support ticket processes once we have confirmed the way forward with the system.
There is a known issue with alterations in formatting of some RDS tables which seems to have arisen as a result of the 17 October deployment. Tactuum is working on a fix and on implementing additional regression testing to prevent this issue recurring.
Recently launched toolkits include:
NHS Lothian Infectious Diseases
Scottish Health Technologies Group – Technology Assessment recommendations
NHS Tayside Anaesthetics and Critical Care projects – an innovative toolkit which uses PowerAutomate to manage review and response to proposals for improvement projects.
If you would like to promote one of your new toolkits through this newsletter, please contact ann.wales3@nhs.scot
A number of toolkits are expected to go live before Christmas, including:
We have had a good response to the recent invitation to sign up to the new Teams channel for RDS editors. This provides a forum for editors to share learning, ideas and questions and we hope to hold regular webinars on topics of interest. The RDS team is in the process of joining participants to the channel and we’d encourage all editors to take part, using the registration form – available in Providers section of the RDS Learning and Support area.
The RDS team has worked with colleagues in NHS Grampian and the Digital Health & Care Innovation Centre to evaluate the impact of the Prevent the progress of diabetes web and mobile app in a small-scale pilot project. This app provides access to local and national resources and services targeted at people with prediabetes, a history of gestational diabetes, or candidates for remission. After just 8 weeks of using the app, 94% of patients reported increased their knowledge and understanding of diabetes, and 88% said it had increased their confidence and motivation to make lifestyle changes, highlighting specific behaviour changes. The learning from this project is informing development of a service model based on tailored support for patient groups with, high, medium and low digital self-efficacy.
Please contact ann.wales3@nhs.scot if you would like to know more about this project.
To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)
To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form - also available in End-user and Provider sections of the RDS Learning and Support area. If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.
With kind regards
Right Decision Service team
Healthcare Improvement Scotland
The Right Decision Service: the national decision support platform for Scotland’s health and care
Website: https://rightdecisions.scot.nhs.uk Mobile app download: Apple Android
What’s New
Tinidazole no longer available
Delaquinium chloride is a licensed 2nd line option
Note IUSTI guideline advice that BV commoner in women with an IUCD
Bacterial Vaginosis is the most common microbiological cause of abnormal vaginal discharge.
It is caused by an overgrowth of anaerobic organisms.
Frequently recurs
NB: Not typically associated with itch, soreness or irritation
Thin, white homogenous discharge coating introitus and vaginal walls, it may look slightly frothy. A characteristic odour is often noted
NB: vulval inflammation is not typical in BV
In genitourinary settings two approaches to the diagnosis of BV are widely used:
Amsel’s criteria and the Hay/Ison criteria 1. Both require microscopy to be available, which is not always the case in sexual health clinics. Where available, microscopy can be used, but syndromic management is supported by national guidelines1,2
The Hay/Ison Criteria (used in the NaSH microscopy page) are:
Grade 0 no bacteria seen
Grade 1 (Normal): Lactobacillus morphotypes predominate
Grade 2 (Intermediate): Mixed flora with some Lactobacilli present, but Gardnerella or Mobiluncus morphotypes also present
Grade 3 (BV): Predominantly Gardnerella and/or Mobiluncus morphotypes. Few or absent Lactobacilli.
Grade 4 Gram positive cocci predominate (consider aerobic vaginitis)
Amsel’s criteria are at least three out of:
(1) Thin, white, homogeneous discharge
(2) Clue cells on microscopy of wet mount
(3) pH of vaginal fluid >4.5
(4) Release of a fishy odour on adding alkali (10% KOH).
History
Diagnosis can be made on the basis of
It is important to take a sexual history to consider the risk of STI and offer STI testing as appropriate as Chlamydia and Gonorrhoea can co-exist. A cervical screening history should be taken as cervical cancer is a differential diagnosis of a smelly discharge. Also consider if a tampon could have been retained.
If possible undertake vulval and speculum examination to visualise any discharge. Inspect the cervix to
exclude any abnormality as a cause of offensive discharge.
Tests options
Not recommended:
High vaginal swabs are of limited value in diagnosing BV as organisms such as gardnerella can be present in 30-40% asymptomatic women. A culture reported as normal does not exclude clinical BV. Microscopy and vaginal pH are far more useful and women reporting recurrent symptoms are better to have a microscopy slide taken.
Asymptomatic women do not need treatment (asymptomatic women should not be being diagnosed as
without symptoms there is no indication to take a test).
General advice
The best ways of preventing BV are not know but avoiding anything that upsets the natural balance of
bacteria in the vagina may help. This includes avoiding:
Use of emollients as a soap substitute for the genital area (available from any pharmacy) is recommended.
BV is more common in women with an IUCD5
If a woman is experiencing recurrent episodes of BV alternative methods can be discussed.
1st line
Metronidazole 400mg oral twice daily 5-7 days (slightly lower relapse rate)
1st line in pregnancy
OR
Metronidazole 2g single oral dose (not recommended in pregnancy)
2nd Line
Clindamycin 300mg oral twice daily 7 days (risk of pseudomembranous colitis)
Or
Dequalinium chloride 10mg vaginal tablets One 10mg vaginal tablet daily for six days6
Insufficient evidence to assess effectiveness but anecdotally useful
Licensed indications
Treatment of BV in adults
Relactagel® : 5 mL( 1 tube) to vagina nightly for 7 nights
Relactagel® is unsuitable for people with an allergy to shellfish as the glycogen is derived from oysters.
There may be a potential risk to a partner who is allergic to shellfish if these have been used.
Balance Activ® is not licenced for treatment
Refer to WOS Pregnancy and STI’s Guideline instead
Non–pregnant women: Not necessary unless symptomatic
Pregnant women: test of cure after a month1
No evidence of benefit in studies of screening and treating male partners
No studies of treatment in female partners although high incidence in female partners of women with BV. If a
female partner is asymptomatic treatment need not be offered routinely.
Consider alternative diagnosis
Check compliance with treatment
Try alternative therapy option - longer course of metronidazole may be more effective than single dose
Sporadic Recurrences
Up to 30% of women have a recurrence within 3 months
Examination and investigation should be considered but may not be necessary if a previous episode of the
signs and symptoms of BV responded to antibiotic treatment, and there are no grounds to suspect an STI or
cervical abnormality.
Frequent Recurrences of Bacterial Vaginosis
This is widely defined as more than four recurrences per year.
Speculum examination should be carried out. The diagnosis should be confirmed with microscopy or HVS.
Negative swabs (or negative dry slide) and persistent symptoms should prompt referral to a sexual health
clinic with microscopy available.
Persistent, symptomatic BV may be associated with the presence of an IUD and an alternative method of
contraception may need to be considered if there is no response to therapy.
Suppressive/preventive treatment
400mg metronidazole oral twice daily for 3 days at start and/or end of menstruation
or
5g 0.75% metronidazole gel intravaginally twice weekly for 16 weeks1
or
Relactagel®: 5 mL (1 tube) nightly to vagina for 2–3 nights after menstruation5
or
Balance Activ RX gel® 5 mL (1 tube) to vagina 1–2 times a week
British National Formulary prices accessed February 2021 NB local contracts may result in
different prices.
Metronidazole 2g | £1.07* |
Metronidazole 400mg b.d. 7 days | £3.50-4.50 |
Metronidazole gel | £4.31 |
Clindamycin 2% Cream | £10.86 |
Clindamycin 300mg b.d. 7 days | £17.84 |
Relactagel 7 x 5ml tubes | £5.25 |
Balance Activ 7 x 5ml tubes | £5.25 |
Delquinium Chloride( Fluomizin) | £6.95 |
Not in BNF : local over labelled pack price 2020
Patient information leaflets
BV information leaflet
https://www.bashhguidelines.org/media/1124/bv_pil_print_2014.pdf (accessed 14/05/2021)
What do you know about...Vaginal health?
http://www.healthscotland.com/documents/3419.aspx
online versions in English, Polish, Chinese, Urdu, Romanian (accessed 14/05/2021)